Group 1: Product Performance and Sales Projections - The main product, Injection Multi-Vitamins (12), is expected to achieve a sales growth of 40% in 2024, with sales revenue exceeding 1.1 billion CNY, and a continued growth trend anticipated for 2025 [2][3] - The sales revenue of An Nao Wan/Pills reached 182 million CNY in 2023, an increase of 81.7 million CNY year-on-year, with a projected growth of over 30% in Q1 2025 [3][4] - The company expects significant growth in Chloride Potassium Sustained-Release Tablets this year [6][8] Group 2: Market Position and Competitive Landscape - Injection Multi-Vitamins (12) maintains over 80% market share due to its competitive landscape and brand advantage [2] - The market for Ginkgo Biloba Injection is favorable, with only three competitors expected to increase sales after the current procurement cycle [3] - The company has a stable partnership with Daiichi Sankyo, contributing approximately 10% of total revenue, around 240 million CNY [4][5] Group 3: Sales and Marketing Strategy - The sales expense ratio decreased from 40.69% in the previous year to 32.48% in 2024, with a further reduction to 28.80% in Q1 2025, indicating improved efficiency [8][9] - The company plans to enhance the competitiveness of An Nao Wan/Pills through improved product qualifications and academic promotion [6][8] - Marketing investments will be adjusted based on product lifecycle and profitability, with increased focus on An Nao Wan/Pills post-medical insurance limit removal [9] Group 4: Future Growth and Development Plans - The company aims to expand its product pipeline through new product approvals and potential acquisitions, focusing on innovative and differentiated products [8][9] - There is an emphasis on maintaining steady growth in existing products while exploring new market opportunities [7][8] - The company is committed to cost reduction and efficiency improvements to sustain profitability [8]

关于公司部分董事及高级管理人员减持股份计划实施完毕的公告 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-058 哈尔滨誉衡药业股份有限公司 公司于 2025 年 5 月 30 日披露了《关于公司部分董事及高级管理人员减持股 份的预披露公告》，公司副总经理李润宝先生、王小航先生及公司董事、副总经 理、董事会秘书刘月寅女士计划自减持计划预披露公告披露之日起 15 个交易日 后的三个月内（2025 年 6 月 24 日-2025 年 9 月 23 日）以集中竞价方式各减持公 司股份 587,500 股（占公司股份总数的 0.03%）、587,500 股（占公司股份总数的 0.03%）、259,619 股（占公司股份总数的 0.01%）。 2025 年 7 月 1 日，公司收到李润宝先生、王小航先生、刘月寅女 ...

Group 1 - The company announced that the share reduction plan by its executives has been completed [1] - Vice General Managers Li Runbao and Wang Xiaohang each reduced their holdings by 587,500 shares, accounting for 0.03% of the company's total shares [1] - Board Secretary and Vice General Manager Liu Yueyin reduced his holdings by 259,600 shares, accounting for 0.01% of the company's total shares [1] Group 2 - The reduction price range for the shares was between 2.9 yuan and 2.92 yuan per share [1] - After the reduction, Li Runbao and Wang Xiaohang each hold 1,762,500 shares, representing 0.08% of the total share capital [1] - Liu Yueyin now holds 779,000 shares, which is 0.03% of the total share capital [1]

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-057 哈尔滨誉衡药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年4月24日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第七届 董事会第三次会议审议通过了《关于使用闲置自有资金进行委托理财的议案》。 同意公司及纳入合并报表范围内的子公司使用不超过人民币39,000万元自有闲 置资金额度在金融机构购买中等或中等以下风险的委托理财产品，在上述投资额 度内，各投资主体资金可以滚动使用，委托理财期限自董事会审议通过之日起一 年内有效，并授权公司经理层负责具体组织实施。具体情况详见2025年4月26日 公司披露于《中国证券报》、《证券时报》及巨潮资讯网http://www.cninfo.com.cn 的《关于使用闲置自有资金进行委托理财的公告》。 2025年5月13日至2025年6月25日，公司使用自有闲置资金24,000万元购买了 理财产品，现将具体情况公告如下： 一、委托理财的情况 （一）中国对外经济 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-056 哈尔滨誉衡药业股份有限公司 关于全资下属公司山西普德药业有限公司 注射用多种维生素（12）通过一致性评价的公告 哈尔滨誉衡药业股份有限公司 注射用多种维生素(12)为静脉补充维生素用药，适用于当口服营养禁忌、不 能或不足（营养不良、吸收不良、胃肠外营养……），需要通过注射补充维生素 的成人及 11 岁以上儿童患者。 该品种由美国 Baxter S.A.开发，最早 1990 年在欧洲上市，商品名 Cernevit。 1999 年进口中国，商品名施尼维他。注射用多种维生素(12)于 2018 年 9 月纳入 《国家基本药物目录(2018 年版)》，于 2020 年 12 月被直接调入《国家基本医 疗保险、工伤保险和生育保险药品目录(2020 年)》，属于国家医保目录乙类品 种。经查询，除美国 Baxter S.A.的原研药品外，国内仅普德药业、山东鲁盛制药 有限公司 2 家获批上市，并通过或视同通过一致性评价。目前在审评中的有重庆 药友制药有限责任公司、内蒙古白医制药股份有限公司和辽宁海思科制药有限公 司。 本公司 ...

Core Viewpoint - Yuheng Pharmaceutical (002437) announced that its wholly-owned subsidiary, Pude Pharmaceutical, received approval from the National Medical Products Administration for the injection of multiple vitamins (12) [1] Group 1: Product Approval and Market Potential - The injection of multiple vitamins (12) has passed the consistency evaluation of generic drug quality and efficacy [1] - The product is intended for adult and pediatric patients aged 11 and above, with projected sales in urban public hospitals and county-level public medical institutions in China amounting to 1.916 billion yuan in 2024 [1] Group 2: R&D Investment - Pude Pharmaceutical has invested approximately 3.6706 million yuan in the consistency evaluation work for this product [1]

Group 1: Company Performance and Financials - The company's revenue has significantly declined compared to 2018 and 2019, primarily due to the sale of Auno (China) Pharmaceutical Co., Ltd. in late 2019, which is no longer included in the consolidated financial statements [2] - In Q1 2025, the company's revenue decreased by 7.06% year-on-year, while net profit attributable to shareholders increased by 15.24% [6] - The company expects stable or slightly declining revenue for 2025, with continued growth in operating performance [6] Group 2: Product and Market Insights - Major products have been subjected to centralized procurement, with significant sales growth expected for the injection of multi-vitamins (over 40% in 2024) [3] - The company has a diverse product portfolio, including traditional Chinese medicine and various injectable products, with a focus on maintaining stable growth in existing products [6][10] - The company is primarily engaged in generic drug business, with plans to explore differentiated generics and high-barrier generics in the short term [10] Group 3: Corporate Structure and Shareholder Information - The company has undergone multiple acquisitions, with goodwill amounting to 369 million yuan as of the end of 2024, with no impairment risks identified [5] - Major shareholders include Shen Zhenyu and others, holding over 20% of total shares, with Shen Zhenyu's stake at approximately 10% as of Q1 2025 [13] - The company completed a share repurchase plan in March 2025, utilizing approximately 80 million yuan to buy back 32.31 million shares, representing 1.42% of the total share capital [11]

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-055 哈尔滨誉衡药业股份有限公司 关于全资下属公司与卫材（中国）药业有限公司 就甲钴胺注射液（商品名：弥可保）签订市场推广服务协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、协议签署时间及主要内容 （一）协议签署时间 2025 年 6 月 1 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）全资 下属公司天津誉衡博达科技有限公司（以下简称"天津博达"）与卫材（中国） 药业有限公司（以下简称"卫材中国药业"）就"甲钴胺注射液"（商品名：弥 可保）签订《市场推广服务协议》（以下简称"协议"）。 （二）协议主要内容 1、卫材中国药业授权天津博达在中国大陆地区（不包括香港特别行政区、 澳门特别行政区和台湾地区）独家推广甲钴胺注射液（商品名：弥可保），授权 期限自 2025 年 6 月 1 日起至协议有效期届满之日终止。 2、天津博达负责提供该产品在上述区域的市场推广服务和其他相关服务。 3、卫材中国药业将按照协议约定向天津博达支付相应的市场推广服务费。 （五 ...

誉衡药业（002437）公告，2025年6月1日，全资下属公司天津誉衡博达科技有限公司与卫材(中国)药业 有限公司就甲钴胺注射液(商品名：弥可保)签订《市场推广服务协议》。协议有效期至2026年3月31 日，到期后若满足条件可自动续约两年至2028年3月31日。卫材中国药业授权天津博达在中国大陆地区 独家推广甲钴胺注射液，天津博达负责市场推广服务及其他相关服务。卫材中国药业将支付市场推广服 务费。此次合作将丰富誉衡药业产品管线，增加营业收入及利润。 ...

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]